• Quality of life: Minnesota Living with Heart Failure, SF-36 [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
• NYHA Class [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]

The principal research objectives are to demonstrate cardioselective beta-blockade using bisoprolol is not inferior to placebo with regard to pulmonary function and improves quality of life in patients with heart failure and coexistent moderate or severe chronic obstructive pulmonary disease with or without significant reversibility. Patients will be followed up for 4 months during which bisoprolol will be up-titrated to the maximum clinically tolerated dose. Health status will be assessed using a generic and two disease specific questionnaires, and pulmonary function by spirometry, body box plethysmography, and cardiopulmonary exercise testing.

• Heart Failure
• Chronic Obstructive Pulmonary Disease

• Drug: Bisoprolol
• Drug: Placebo

• Experimental: Bisoprolol
• Placebo Comparator: Identical appearance matching placebo

Inclusion Criteria:

• symptomatic NYHA II or III chronic heart failure
• left ventricular systolic dysfunction
• moderate or severe chronic obstructive pulmonary disease
• with or without significant reversibility

Exclusion Criteria:

• beta−blocker contraindications
• non−dihydropyridine (diltiazem / verapamil) calcium channel blockers
• recent coronary percutaneous intervention or coronary artery bypass graft surgery
• haemodynamically significant valvular disease or hypertrophic cardiomyopathy.
• active myocarditis or pericarditis.
• recent cerebrovascular accident or transient ischaemic attack
• serious concurrent systemic disease, such as malignancy, resulting in likely reduced life expectancy
• pregnancy, childbearing potential with inadequate contraception, breast feeding